Influence of magnesium orotate on cardiovascular risks


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article discusses the role of magnesium metabolism disorders in the pathogenesis of cardiovascular diseases, and the possibility of the use of magnesium orotate (Magnerot) for their treatment. Magnesium is a natural physiological Ca2+ antagonist, a universal controller of biochemical and physiological processes in the body; it provides ATP hydrolysis by inhibiting the uncoupling of oxidation and phosphorylation; it regulates glycolysis, lactate accumulation; it promotes fixation of K+ in cells, providing a polarization of cell membrane, and controls the spontaneous electrical activity of nerve tissue and the cardiac conduction system; Mg2+ ions are involved in the activity of the anticoagulation system and control the normal functioning of cardiomyocytes, so magnesium is a universal cardioprotector. The role of magnesium deficiency in the development of mitral valve prolapse, cardiac arrhythmias, arterial hypertension, and so on is discussed. Magnesium has very essential role in the treatment of acute myocardial infarction. Successful results of use of magnesium orotate in cardiovascular diseases, caused by magnesium deficiency, are presented. Due to accumulation of knowledge and additional large-scale studies, range of indications for the use of magnesium preparations will be indisputably significantly expanded.

Full Text

Restricted Access

About the authors

Anatoliy Ivanovich Martynov

A.I. Yevdokimov Moscow state university of medicine and dentistry

Email: mailbox@rnmot.ru
academician of Russian academy of sciences, MD, professor, Department of hospital therapy № 1

Yevgeniya Vladimirovna Akatova

A.I. Yevdokimov Moscow state university of medicine and dentistry

Email: akev@list.ru
MD, professor, Department of hospital therapy № 1

Olesya Petrovna Nikolin

A.I. Yevdokimov Moscow state university of medicine and dentistry

Email: nikolin71@mail.ru
PhD, assistant professor, Department of hospital therapy № 1

Inna Vladimirovna Urlaeva

A.I. Yevdokimov Moscow state university of medicine and dentistry

Email: innich1@yandex.ru
assistant, Department of hospital therapy № 1

References

  1. Лазебник Л.Б., Дроздова С.Л. Коррекция магниевого дефицита при сердечно-сосудистой патологии. Кардиология. 1997;5:103-4. [Lazebnik L.B., Drozdova S.L. Correction of magnesium deficiency in cardiovascular disease. Kardiologiia. 1997;5:103-4 (in Russian)]
  2. Мартынов А.И., Акатова E.B., Николин О.П. Клиническая эффективность о ротата магния у пациентов с нарушениями ритма и артериальной гипертонией при пролапсе митрального клапана. Кардиоваскулярная терапия и профилактика. 2009;8:8-12. [Martynov A.I., Akatova Ye.V., Nikolin O.P. Clinical effectiveness of magnesium orotate in patients with arrhythmias and arterial hypertension with mitral valve prolapse. Cardiovascular therapy and prevention. 2009;8:8-12 (in Russian)]
  3. Мартынов А.И., Акатова E.В. Опыт пятнадцатилетнего применения препаратов магния у больных с пролапсом митрального клапана. Кардиология. 2011 ;6:60-5. [Martynov A.I., Akatova Ye.V. Experience of fifteen years of the use of magnesium preparations in patients with mitral valve prolapse. Kard io log і ia. 2011;6:60-5 (in Russian)]
  4. Нечаева Г.И. Вариабельность сердечного ритма у пациентов молодого возраста с дисплазией соединительной ткани. Дисплазия соединительной ткани. 2008;1:12-5. [Nechaeva G.I. Heart rate variability in young patients with connective tissue dysplasia. Connective tissue dysplasia. 2008; 1:12-5 (in Russian)]
  5. Трешкур T.B., Киреенков И.С., Капанадзе C.Т. Случай идиопатической фибрилляции желудочков, индуцированный вагусной активностью. Вестник аритмологии. 2000;20:76-9. [Treshkur T.V., Kireenko I.S., Kapanadze S.T. Case of idiopathic ventricular fibrillation induced with vagal activity. Bulletin of arrhythmology. 2000;20:76-9 (in Russian)]
  6. Царегородцев Д.А. Проблема медикаментознорезистентных аритмий. Российский кардиологический журнал. 2001;2:2-9. [Tsaregorodtsev D.A. Problem of drug resistant arrhythmias. Russian journal of cardiology. 2001;2:2-9 (in Russian)]
  7. Шилов A.M., Святов И.С., Чубаров М.В. Результаты применения магнийсодержащих препаратов для лечения и профилактики гипер- и дислипидемии. Клиническая медицина. 1998;4:35-7. [Shilov М.А., Svyatov I.S., Chubarov M.V. Results of the use of magnesium preparations for the treatment and prevention of hyper- and dyslipidemia. Clinical medicine. 1998;4:35-7 (in Russian)]
  8. Шилов A.M., Чубаров M.B., Святов И.С. Препараты магния в коррекции основных факторов риска развития ишемической болезни сердца. Российские медицинские вести. 1999;3:51-3. [Shilov М.А., Chubarov V.M., Svyatov I.S. Magnesium preparations in the correction of the major risk factors of coronary heart disease. Russian medical news. 1999;3:51-3 (in Russian)]
  9. Шилов A.M., Мельник M.B., Соколинская И.Ю. Влияние препаратов магния на гемореологические свойства крови при артериальной гипертонии. Кардиология. 2000: Материалы российской конференции. Москва, 2000:223. [Shilov М.А., Melnik M.V., Sokolinskaya I.Yu. Influence of magnesium preparations on hemorheological properties of blood in arterial hypertension. Kardiologiia. 2000: Proceedings of the Russian conference. Moscow, 2000:223 (in Russian)]
  10. Devereux R.B., Kramer-Fox R., Shear M.K., Kligfield P., Pini R., Savage D.D. Diagnosis and classification of severity of mitral valve prolapse: methodologic, biologic and prognostic considerations. Am. Heart J. 1987;1 13(5):1265-80.
  11. Ekmekci O.B, Donma O., Tunckale A. Angiotensin-converting enzyme and metals in untreated essential hypertension. Biol. Trace Elem. Res. 2003;95(3):203-10.
  12. Elin R.J. Magnesium metabolism in health and disease. In: Disease-a-Month. (Ed. R.C. Bone). Year Book Medical Publishers, Inc. 1988.
  13. Galland L.D., Baker S.M., McLellan R.K. Magnesium deficiency in the pathogenesis of mitral valve prolapse. Magnesium. 1996;5(3-4):165-74.
  14. Geleijnse J.M, Witteman J.C, Bak A.A, den Breeijen J.H, Grobbee D.E. Reduction in blood pressure with a low sodium, high potassium, high magnesium salt in older subjects with mild to moderate hypertension. BMJ. 1994;309(6952):436-40.
  15. Glesby M.J., Pyentz R.E. Association of mitral valve prolaps and systemic abnornalities of connective tissue. A phenotypic continuum. JAMA. 1989;262(4):523-8.
  16. Jee S.H., Miller E.R., Guallar E., Singh V.K., Appel L.J., Klag M.J. The effect of magnesium supplementation on blood pressure: a meta-analysis of randomized clinical trials. Am. J. Hypertens. 2002;15:691-6.
  17. Ma J., Folsom A.R., Melnick S.L., Eckfeldt J.H., Sharrett A.R., Nabulsi A.A., Hutchinson R.G., Metcalf P.A. Associations of serum and dietary magnesium with cardiovascular disease, hypertension, diabetes, insulin, and carotid arterial wall thickness: the ARIC study. Atherosclerosis Risk in Communities Study. J. Clin. Epidemiol. 1995;48:927-40.
  18. Peacock J.M., Folsom A.R., Arnett D.K., Eckfeldt J.H., Szklo M. Relationship of serum and dietary magnesium to incident hypertension: the Atherosclerosis Risk in Communities (ARIC) Study. Ann. Epidemiol. 1999;9:159-65.
  19. Woods K.L., Fletcher S., Roffe C., Haider Y. Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Megnesium Intervention Trial (LIMIT-2). Lancet. 1992;339:1553-8.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies